Aeris Capital et al. invest in Affimed Therapeutic series-D
Aeris Capital and existing investors have backed German biotech company Affimed Therapeutic in a €15.5m series-D round.
Participating investors include BioMedInvest, LSP Life Sciences Partners, Novo Nordisk and Orbimed. The company will use the funding for the clinical development of two new tetravalent bispecific antibody format (TandAb) products, AFM11 and AFM13.
Affimed Therapeutic previously received funding rounds in 2003 (€2m), 2007 (€25m), 2008 (€5m) and 2010 (€20m).
Company
Spun out of the German Cancer Research Centre (DKFZ), Heidelberg, and led by CEO Dr Adi Hoess, Affimed has generated a range of drug candidates based on its proprietary TandAb antibody technology. The drugs focus on the treatment of oncological and anti-inflammatory diseases. Affimed employs 30 people.
More on Early-stage
Sidekick spinoffs: Insurtech scale-ups attract PE interest
Investment set to break EUR 1.1bn mark this year as sponsors seek for rising stars
World Fund leads EUR 128m raise for quantum computing group IQM
Series-A2 for Finnish startup focused on combating the climate crisis also backed by the EIB
Gorillas raises circa USD 1bn in Delivery Hero-led Series C
New funding comes just seven months after a Series B, with the company doubling in value
French mega-rounds shoot up in 2021
France has already seen as many rounds of EUR 100m and above than in 2019 and 2020 combined, Unquote Data shows
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater